What were the key takeaways from cbdMD's earnings call?

What were the key takeaways from cbdMD’s earnings call?

What is cbdMD's gross profit margin?

What is the market's earnings forecast for cbdMD next quarter?

What guidance did cbdMD's management provide for the next earnings period?

What does cbdMD do and what are its main business segments?

What factors drove the changes in cbdMD's revenue and profit?

Did cbdMD beat or miss consensus estimates last quarter?

- **Revenue Growth**: 12% sequential increase to $5 million, driven by DTC sales (72%) and wholesale growth (17% YoY).
- **Strategic Acquisition**: Bluebird Botanicals adds IP, regulatory strength, and customer base, with integration focused on supply chain and marketing.
- **Financial Strength**: $3.4 million cash, $5.4 million working capital, and $36,000 EBITDA loss, up from prior quarters.
- **Regulatory Focus**: Advocating for HEMP Act to counter restrictive hemp legislation, positioning for Medicare CBD pilot program.

**【Management Opening Remarks】**
- CEO Ronan Kennedy highlighted three consecutive quarters of sequential revenue growth, with Q1 2026 revenue at $5 million, a 12% increase from Q4 2025.
- Emphasized progress in stabilizing operations, reducing costs, and regaining NYSE compliance.
- Announced the acquisition of Bluebird Botanicals, adding $2.25 million in Series C preferred financing and a $20 million equity line of credit (ELOC) for liquidity flexibility.

**【CEO Commentary】**
- **Revenue Performance**: DTC sales accounted for 72% of revenue, while wholesale grew 17% YoY, driven by core cbdMD and Oasis beverage brand momentum.
- **Strategic Acquisitions**: Bluebird Botanicals acquisition adds intellectual property, regulatory expertise, and a loyal customer base, with integration focused on supply chain and marketing synergies.
- **Regulatory Environment**: Navigating restrictive hemp legislation (H.R. 5371) while supporting bipartisan HEMP Act for regulatory clarity.
- **Financial Health**: Ended Q1 with $3.4 million in cash and $5.4 million in working capital, up from prior quarters, and a $36,000 EBITDA loss.

**【CFO Financial Commentary】**
- **Top Line**: Net sales $5 million (down 2% YoY, +12% sequential) with 60% gross margin (down 6% YoY due to warehouse costs and wholesale mix).
- **Bottom Line**: Net loss $325,000 ($0.04/share) vs $1 million ($1.73/share) YoY, driven by Series A preferred stock conversion.
- **Liquidity**: $3.3 million cash increase from Series C financing, with $812,000 cash used in operations due to working capital investments.

**【Q&A Highlights】**
- **Bluebird Integration**: Maintaining separate brand identities but exploring SKU synergies and cross-marketing opportunities.
- **Herbal Oasis Seltzers**: Small contribution to date, with growth expected this year but no specific sales figures disclosed.
- **Regulatory Strategy**: Engaging with policymakers to advocate for sensible CBD regulations and Medicare pilot program participation.

cbdMD, Inc. (YCBD) Q1 2026 Earnings Call Transcript

- **Operational Turnaround**: 3rd consecutive year of improved financials, with operating loss down 36% and EBITDA loss reduced by 47%.
- **Oasis Growth Driver**: Beverage brand expansion into 9 states, targeting $30B Medicare reimbursement opportunity.
- **Financial Strength**: $2.2M cash, $3.3M working capital, and $20M equity line for flexible growth.
- **Regulatory Risk Management**: Cautious approach to THC limits, with contingency plans to navigate regulatory shifts.
- **Shareholder Dilution Control**: Series C financing at favorable terms, with no immediate plans for significant equity issuance.

**【CEO Opening Remarks】**
- Fiscal 2025 marked the third consecutive year of operational improvement, with a $1.2 million reduction in operating loss to $2.1 million and adjusted EBITDA improving from a $1.7 million loss to a $900,000 loss.
- The company introduced the Oasis beverage brand, achieving distribution in 9 states and seeing improving case sell-through. This positions cbdMD in the fast-growing functional alcohol alternative market.
- Balance sheet strength was restored through $7 million in net book value increase, elimination of $2.25 million in preferred dividends, and a $20 million equity line of credit for future capital flexibility.
- The White House's executive order supporting Medicare reimbursement for CBD products presents a potential $30 billion market opportunity, though implementation details remain unclear.

**【CFO Financial Commentary】**
- FY2025 net sales: $19.1 million (down 2% YoY), with e-commerce sales at $14.7 million (6% YoY decline) and wholesale sales at $4.5 million (18% YoY growth).
- Gross margin improved to 63% (vs. 62% in FY2024), driven by SKU rationalization and cost control.
- SG&A expenses decreased 8% YoY to $14.1 million, contributing to a $2.1 million operating loss (vs. $3.3 million prior year).
- Cash and working capital improved to $2.2 million and $3.3 million, respectively, enabling a strong liquidity position for FY2026.

**【Q&A Highlights】**
- **Growth Drivers**: CEO emphasized Oasis as the primary growth engine, with plans to scale distribution in 2026. Core cbdMD brand is stabilizing but not expected to drive significant growth.
- **D2C Decline**: Attributed to shifting consumer preference to beverages and SKU rationalization, with signs of stabilization in Q4 2025.
- **Regulatory Outlook**: While Medicare reimbursement could boost demand, the company is cautious due to ongoing regulatory uncertainty (e.g., H.R. 5371 THC limits). Contingency plans are in place to adapt to changing regulations.
- **Capital Allocation**: FY2026 focus on disciplined marketing spend and selective inventory builds, with Oasis receiving priority investment in Q1 2026.
- **Share Count**: Pro forma fully diluted shares at ~10.6 million (including 1.7M Series B and 1.0M Series C preferred shares). No material changes to equity structure expected from new executive compensation plan.


cbdMD, Inc. (YCBD) Q4 2025 Earnings Call Transcript

- **Revenue stabilization with challenges**: 10.9% YoY decline but QoQ stabilization. Oasis expansion to seven states, direct-to-consumer sales growth in July.
- **Strong financial health**: 61% gross margin, $1.1M cash, and halved year-to-date loss.
- **Regulatory focus**: Proactive engagement amid state-level changes, federal cannabis schedule progress.
- **Strategic opportunities**: Evaluating deals, cautious on reverse stock split.
- **Growth risks**: Regulatory delays in wholesale, gross margin pressure from Oasis.

**【CEO Summary Section】**
- **Mixed quarter with progress and challenges**: Revenue declined 10.9% YoY but stabilized QoQ. Oasis expanded to seven states, with Tennessee and Minnesota added post-Q3. Direct-to-consumer sales accelerated in July, driven by improved digital marketing and influencer partnerships.
- **Operational focus on regulatory environment**: Faced delays in wholesale due to state-level regulatory changes, but proactive engagement with regulators and industry associations. Encouraged by potential federal cannabis schedule changes.
- **Financial strength**: Gross margin remained strong at 61%, with financial flexibility from eliminating preferred dividends.

**【CFO Financial Commentary】**
- **Revenue performance**: Total net sales $4.6M (10.9% YoY decline), e-commerce $3.6M (78% of total), wholesale $1M (17.1% YoY decline). Gross profit 61%, flat QoQ.
- **Cost management**: SG&A $3.7M (flat YoY), with increased marketing and insurance accrual. Net loss $895K vs. $459K YoY, but year-to-date loss halved to $1.3M.
- **Liquidity improvement**: Cash $1.1M, working capital $2M (vs. deficit in prior year). Inventory up $300K for key SKUs and Oasis.

**【Q&A Key Highlights】**
- **Strategic opportunities**: Increased deal flow, focusing on accretive, low-risk partnerships. No immediate plans for reverse stock split.
- **Gross margin dynamics**: Decline due to regulatory costs and lower-margin Oasis. Expect stabilization in low 60s as scale improves.
- **Wholesale strategy**: Prioritizing states with stable regulations (e.g., Georgia), deepening partnerships, and cautious expansion.
- **Marketing efficiency**: Reduced CAC post-March leadership changes, focusing on customer acquisition and retention.
- **Oasis growth**: Cautious expansion with seven states, pending segment materiality. No timeline for separate reporting.


cbdMD Inc (YCBD) Q3 2025 Earnings Call Transcript

- **Capital Structure Reset**: $6.7M preferred dividend conversion slashes annual obligations by $4M, unlocking $7M+ book value.
- **Operational Efficiency**: 19.5% YoY SG&A reduction drives 71% EBITDA improvement to -$197K.
- **Growth Catalysts**: Herbal Oasis poised for Q4 2025 lift with $4B+ THC seltzer market tailwind.
- **Strategic Flexibility**: Debt-free, $1.7M cash, and clean cap table enable M&A and expansion.

**【CEO Opening Remarks】**
- Achieved two key goals: revenue growth/profitability and capital structure resolution.
- Completed Series A Preferred Stock conversion, raising pro forma non-GAAP adjusted book value to $7M (vs. $0.67M prior) and eliminating $4M annual dividends.
- Reverse stock split reduces shares outstanding to 8.9M, achieving compliance with NYSE American listing standards.
- Now debt-free with no warrant overhang, enabling strategic flexibility for M&A and growth initiatives.

**【CFO Financial Highlights】**
- Q2 2025 net sales: $4.7M (+8.6% YoY), driven by 22% YoY wholesale growth.
- Gross margin: 62% (industry-leading), despite one-time warehouse cost increases.
- SG&A expenses: $3.5M (-19.5% YoY) due to cost optimization (e.g., $1.8M 6-month savings).
- Loss from operations: $485K (vs. $1.5M YoY), with non-GAAP EBITDA improving 71% YoY to -$197K.
- Cash: $1.7M; working capital deficit: -$3.7M (includes $1M accrued preferred dividends).

**【Q&A Key Takeaways】**
1. **Herbal Oasis Expansion**: 
   - Launched in 3 states (AL, FL, NC) with new distribution partnerships.
   - Projected to contribute meaningfully to Q4 2025 revenue.
   - Category growth: $4B+ by 2030 (Euromonitor).
2. **Strategic Opportunities**: 
   - Evaluating M&A in cannabis and adjacent categories (e.g., functional beverages).
   - Shelf registration expected to reopen in Q4 2025 post-audit.
3. **Liquidity Outlook**: 
   - Current cash burn rate ($200K/Q) sustainable through 2026.
   - Targeting positive EBITDA in H2 2025.
   - No material liabilities beyond working capital.


cbdMD, Inc. (YCBD) Q2 2025 Earnings Call Transcript

- **Historic Profitability**: Q1 marked first positive net income and EBITDA, signaling a fundamental shift to profitability.
- **Revenue Resilience**: 12% QoQ revenue growth, with wholesale sales up 22% YoY, offsetting e-commerce headwinds.
- **Cost Efficiency**: 26% YoY SG&A reduction enabled $214K EBITDA, a $912K improvement vs. prior year.
- **Strategic Expansion**: Debt-free status and Oasis beverage launches set stage for 2025 growth, targeting full-year profitability.
- **Shareholder Focus**: 1:13 preferred conversion proposal balances stakeholder needs while addressing NYSE compliance risks.

**【CEO Opening Remarks】**
- Achieved **first-ever positive net income** and **$214,000 non-GAAP adjusted EBITDA** in Q1 2025, marking a historic turnaround.
- Revenue rebounded sequentially, with gross margins stabilizing at 66% and SG&A expenses reduced by 26% year-over-year.
- Launched **Oasis Social Tonics**, a hemp-derived beverage line, with national retailers ready to distribute upon final contract signings.
- Emphasized financial discipline, with a focus on 2025 full-year profitability and sustainable growth.

**【CFO Financial Breakdown】**
- Total net sales: $5.1M (5% YoY decrease, 12% QoQ increase), driven by 22% growth in wholesale sales.
- E-commerce sales: $3.9M (10% YoY decrease), accounting for 77% of total revenue.
- Key cost reductions: Payroll (-33%), professional fees (-42%), and elimination of HQ lease expenses.
- Cash position: $2M as of Q1 end, with debt-free status post-convertible note conversion.

**【Capital Structure Update】**
- Proposed 1:13 conversion ratio for Series A preferred shares, aiming to resolve capital structure and regain NYSE compliance by December 2025.
- Shareholder engagement highlights: 90% of as-converted common stock under proposed terms, balancing stakeholder interests.

**【Q&A Highlights】**
- **Oasis Beverage Performance**: Early DTC margins slightly tighter than core products, but wholesale partnerships expected to drive incremental EBITDA.
- **Liquidity Outlook**: Maintained 8+ quarters of runway, with normalized working capital trends expected in coming quarters.
- **Industry Trends**: Hemp-derived beverages outperforming broader CBD category, with Oasis positioned to capitalize on 2025 growth momentum.

Actual							-64.8	-141.4544	-64.8	-86.4	7.2	-25.2	-126			-28.8	-13.92	-9.28	-46.96	-5.36	-10.8	-1.2	0	-1.76	-1.9	-0.21	2.78	-0.04
Forecast							-12	-3.6	-7.2	-10.8	-14.4	-16.2	-9	-32.4	-18	-126	-28.8	-21.6	-6.08	-5.92	-6	-4.96	-3.6	-2.96	-1.6	-0.02	-0.07	-0.06
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-440.00%	-3829.29%	-800.00%	-700.00%	+150.00%	-55.56%	-1300.00%	0.00%	0.00%	+77.14%	+51.67%	+57.04%	-672.37%	+9.46%	-80.00%	+75.81%	+100.00%	+40.54%	-18.75%	-950.00%	+4071.43%	+33.33%

Actual	--	--	--	--	--	--	10.64M	11.70M	12.33M	11.80M	10.56M	9.80M	9.32M	--	--	6.09M	6.24M	6.12M	5.71M	5.38M	4.38M	5.17M	4.56M	5.11M	4.75M	4.61M	4.72M	5.02M
Forecast	--	--	--	--	--	--	9.57M	11.20M	12.15M	12.62M	12.55M	11.25M	13.25M	10.00M	10.50M	11.50M	12.00M	13.40M	6.13M	5.80M	5.40M	4.93M	4.81M	5.19M	5.14M	5.30M	4.70M	4.86M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+11.18%	+4.46%	+1.46%	-6.49%	-15.85%	-12.89%	-29.65%	0.00%	0.00%	-47.09%	-48.00%	-54.33%	-6.85%	-7.34%	-19.00%	+5.03%	-5.20%	-1.42%	-7.63%	-13.13%	+0.40%	+3.27%

YCBD

YCBD fundamentals

YCBD Q1 2026 Earnings

Earnings Call

You can ask Aime

YCBD

YCBD fundamentals

YCBD Q1 2026 Earnings

Earnings Call

YCBD Earnings Call Summary for Q1/20264:20 PM on Feb 17, 2026

YCBD Earnings Call Summary for Q4/20254:20 PM on Dec 19, 2025

YCBD Earnings Call Summary for Q3/20254:20 PM on Aug 14, 2025

YCBD Earnings Call Summary for Q2/20254:20 PM on May 15, 2025

YCBD Earnings Call Summary for Q1/20254:20 PM on Feb 13, 2025

You can ask Aime